30 Participants Needed

Skin Hydration Sensor for Sickle Cell Disease

EN
MM
Overseen ByManzoor Mohideen, PhD
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Enrico Novelli
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This study will validate the diagnostic accuracy of a cutaneous hydration sensor. This sensor will also be evaluated for its feasibility as a point-of-care device for the assessment of hydration status and its potential to guide hydration therapy in patients with sickle cell disease (SCD).

Do I need to stop my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the Skin Hydration Sensor treatment for sickle cell disease?

Research suggests that hydration can reduce the severity of sickle cell disease, and the Skin Hydration Sensor could help monitor and manage hydration levels effectively. This is supported by studies showing that better hydration correlates with reduced painful crises in sickle cell patients.12345

Is the Skin Hydration Sensor safe for use in humans?

The Skin Hydration Sensor has been tested on over 200 patients in a dermatology clinic and 16 healthy participants, showing it is noninvasive, reusable, and safe for monitoring skin hydration without any reported safety issues.678910

How does the Skin Hydration Sensor treatment for Sickle Cell Disease differ from other treatments?

The Skin Hydration Sensor is unique because it is a noninvasive, wireless device that measures skin hydration and transmits data to a smartphone, unlike traditional treatments that may involve medication or more invasive procedures. This sensor provides a novel way to monitor skin health, which can be particularly useful for managing conditions like Sickle Cell Disease where skin hydration may be a concern.7891112

Research Team

EN

Enrico Novelli, MD

Principal Investigator

University of Pittsburgh

Eligibility Criteria

This trial is for individuals aged 12 or older who have been diagnosed with Sickle Cell Disease, including various genotypes like SS, SC, and others. Participants must be able to give legal consent to all study procedures. Those under 12 or currently in other clinical trials for experimental therapies cannot join.

Inclusion Criteria

I have been diagnosed with Sickle Cell Disease.
Participants that provide legally effective consent to all study procedures
I am 12 years old or older.

Exclusion Criteria

I am under 12 years old.
You are currently participating in another clinical trial testing an experimental treatment.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants' skin hydration is measured at baseline state of health using the Delfin MoistureMeterEpiD hydration sensor.

Approximately 2 hours
1 visit (in-person)

Crisis Assessment

Skin hydration, serum osmolality, hyperadhesion, elongation index, point of sickling, and urine osmolality are measured before and after fluid resuscitation therapy during a vaso-occlusive crisis (VOC) or vaso-occlusive episode (VOE).

Approximately 2 hours per assessment
2 visits (in-person) during VOC or VOE

Follow-up

Participants are monitored for safety and effectiveness after the assessments.

4 weeks

Treatment Details

Interventions

  • Skin Hydration Sensor
Trial OverviewThe trial is testing a new skin hydration sensor designed to accurately assess hydration levels in patients with Sickle Cell Disease. The goal is to see if this sensor can work as an easy-to-use device at the point of care and help guide proper hydration therapy.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Skin Hydration SensorExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Enrico Novelli

Lead Sponsor

Trials
2
Recruited
50+

Enrico M Novelli

Lead Sponsor

Trials
2
Recruited
50+

Findings from Research

A new microfluidic-informatics system was developed to measure vaso-occlusion in sickle cell disease, showing increased occlusion events in patients with the most severe hemoglobin SS type, which helps in assessing disease severity.
The system can also evaluate the impact of hydration on reducing disease severity, suggesting it could be a useful tool for testing therapeutic strategies in high-risk patients.
A microfluidic-informatics assay for quantitative physical occlusion measurement in sickle cell disease.Zhang, X., Chan, T., Carbonella, J., et al.[2022]
In a study of 16 children with homozygous sickle cell disease followed for an average of 6.8 years, higher rates of painful crises were linked to better red blood cell hydration and deformability, indicating that cellular hydration plays a significant role in vasoocclusive severity.
Both red cell deformability and hemoglobin concentration were found to be independent predictors of painful crisis incidence, suggesting that managing these factors could help in understanding and potentially reducing the frequency of painful episodes in sickle cell disease.
The incidence of painful crisis in homozygous sickle cell disease: correlation with red cell deformability.Lande, WM., Andrews, DL., Clark, MR., et al.[2021]
The study enrolled 37 participants with sickle cell disease over 6 months, successfully using electronic patient-reported outcomes (ePRO) and actigraphy to monitor pain and activity, revealing significant changes in pain and functionality on days with vaso-occlusive crises (VOCs).
Biomarkers collected during VOCs showed significant alterations compared to baseline values, indicating that these biological changes could help in identifying and assessing VOCs more effectively in clinical settings.
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers.Pittman, DD., Hines, PC., Beidler, D., et al.[2021]

References

A microfluidic-informatics assay for quantitative physical occlusion measurement in sickle cell disease. [2022]
The incidence of painful crisis in homozygous sickle cell disease: correlation with red cell deformability. [2021]
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. [2021]
Electrical Impedance Characterization of Erythrocyte Response to Cyclic Hypoxia in Sickle Cell Disease. [2020]
Med-vest: A wearable sensory platform. [2020]
Design and Analysis of a Continuous and Non-Invasive Multi-Wavelength Optical Sensor for Measurement of Dermal Water Content. [2021]
Reliable, low-cost, fully integrated hydration sensors for monitoring and diagnosis of inflammatory skin diseases in any environment. [2022]
Wireless, Soft Sensors of Skin Hydration with Designs Optimized for Rapid, Accurate Diagnostics of Dermatological Health. [2023]
Skin conductance; validation of Skicon-200EX compared to the original model, Skicon-100. [2019]
Comparative study of normal and rough human skin hydration in vivo: evaluation with four different instruments. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Skin hydration state estimation using a fiber-optic refractometer. [2018]
Skin moisture assessment using Hydration Sensor Patches coupled with smartphones via Near Field Communication (NFC). A pilot study with the first generation of patches that allow self-recordings of skin hydration. [2021]